Results of PDR treatments: The AMC PDR experience

B. R. Pieters, E. D. Geijsen

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review


Pulsed-dose-rate (PDR) brachytherapy has been introduced for the treatment of intermediate-/high-risk prostate cancer. A dose of 28–35 Gy PDR brachytherapy is given as a boost to external beam radiotherapy of 46–50 Gy. The reported 5-year biochemical-free survival is 85.6–89.5 %. The incidence of grade 2–3 rectal complications is limited (12–15 %). The incidence of grade 2–3 urinary toxicity is 15–26.9 %. The figures on biochemical control and late toxicity are similar to HDR experience. PDR for prostate brachytherapy can be considered as an alternative to HDR brachytherapy.
Original languageEnglish
Title of host publicationInterstitial Prostate Brachytherapy
PublisherSpringer Berlin Heidelberg
ISBN (Electronic)9783642364990
ISBN (Print)9783642364983
Publication statusPublished - 2013
Externally publishedYes

Publication series

NameInterstitial Prostate Brachytherapy

Cite this